Related references
Note: Only part of the references are listed.Novel agonist and antagonist radioligands for the GLP-2 receptor. Useful tools for studies of basic GLP-2 receptor pharmacology
Sarina Gadgaard et al.
BRITISH JOURNAL OF PHARMACOLOGY (2022)
Investigating GIPR (ant)agonism: A structural analysis of GIP and its receptor
Florent X. Smit et al.
STRUCTURE (2021)
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Enzymes
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2021)
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2021)
Exendin(9-39)NH2: Recommendations for clinical use based on a systematic literature review
Laerke Smidt Gasbjerg et al.
DIABETES OBESITY & METABOLISM (2021)
Structural insights into hormone recognition by the human glucose-dependent insulinotropic polypeptide receptor
Fenghui Zhao et al.
ELIFE (2021)
GLP-1 Val8: A Biased GLP-1R Agonist with Altered Binding Kinetics and Impaired Release of Pancreatic Hormones in Rats
Wijnand J. C. van der Velden et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2021)
GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals
Laerke S. Gasbjerg et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Francis S. Willard et al.
JCI INSIGHT (2020)
A unique hormonal recognition feature of the human glucagon-like peptide-2 receptor
Wen Sun et al.
CELL RESEARCH (2020)
GLP-2 and GIP exert separate effects on bone turnover: A randomized, placebo-controlled, crossover study in healthy young men
Kirsa Skov-Jeppesen et al.
BONE (2019)
Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats
Sara Baldassano et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals
Laerke S. Gasbjerg et al.
DIABETES (2019)
Human GIP(3-30)NH2 inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptors
Maria Buur Nordskov Gabe et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers
Michael J. Curtis et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
Postprandial Effects of Individual and Combined GIP and GLP-1 Receptor Antagonization in Healthy Subjects
Laerke S. Gasbjerg et al.
DIABETES (2018)
Glucagon-like peptide 1 in health and disease
Andreas Andersen et al.
NATURE REVIEWS ENDOCRINOLOGY (2018)
Insulin Secretion Depends on Intra- islet Glucagon Signaling
Berit Svendsen et al.
CELL REPORTS (2018)
GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study
Laerke S. Gasbjerg et al.
DIABETOLOGIA (2018)
GLP-2 Dysregulates Hepatic Lipoprotein Metabolism, Inducing Fatty Liver and VLDL Overproduction in Male Hamsters and Mice
Jennifer Taher et al.
ENDOCRINOLOGY (2018)
Full monty of family B GPCRs
Thue W. Schwartz et al.
NATURE CHEMICAL BIOLOGY (2017)
GIP(3-30)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release
A. H. Sparre-Ulrich et al.
BIOCHEMICAL PHARMACOLOGY (2017)
N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor
L. S. Hansen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
Glucagon-like peptide-2 treatment improves glucose dysmetabolism in mice fed a high-fat diet
Sara Baldassano et al.
ENDOCRINE (2016)
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Brian Finan et al.
NATURE MEDICINE (2015)
Physiology and Pharmacology of the Enteroendocrine Hormone Glucagon-Like Peptide-2
Daniel J. Drucker et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 76 (2014)
Direct Effects of Exendin-(9,39) and GLP-1-(9,36)amide on Insulin Action, -Cell Function, and Glucose Metabolism in Nondiabetic Subjects. Diabetes 2013;62:2752-2756
M. Sathananthan et al.
DIABETES (2014)
A novel truncated glucagon-like peptide 2 (GLP-2) as a tool for analyzing GLP-2 receptor agonists
Kazuto Yamazaki et al.
BIOMEDICAL RESEARCH-TOKYO (2013)
Central GLP-2 Enhances Hepatic Insulin Sensitivity via Activating PI3K Signaling in POMC Neurons
Xuemei Shi et al.
CELL METABOLISM (2013)
Exaggerated Glucagon-Like Peptide 1 Response Is Important for Improved β-Cell Function and Glucose Tolerance After Roux-en-Y Gastric Bypass in Patients With Type 2 Diabetes
Nils B. Jorgensen et al.
DIABETES (2013)
Effect of glucagon-like peptide-2 exposure on bone resorption: Effectiveness of high concentration versus prolonged exposure
Carsten Askov-Hansen et al.
REGULATORY PEPTIDES (2013)
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Brian Finan et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
GLP-2 receptor in POMC neurons suppresses feeding behavior and gastric motility
Xinfu Guan et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2012)
The Family B1 GPCR: Structural Aspects and Interaction with Accessory Proteins
Alain Couvineau et al.
CURRENT DRUG TARGETS (2012)
Endogenous GLP-1 Regulates Postprandial Glycemia in Humans: Relative Contributions of Insulin, Glucagon, and Gastric Emptying
Mathias Nicolaus et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Four-month treatment with GLP-2 significantly increases hip BMD A randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD
Dennis B. Henriksen et al.
BONE (2009)
Glucagon-Like Peptide-2 Increases Intestinal Lipid Absorption and Chylomicron Production via CD36
Joanne Hsieh et al.
GASTROENTEROLOGY (2009)
GLP-1 regulates gastroduodenal motility involving cholinergic pathways
J. Schirra et al.
NEUROGASTROENTEROLOGY AND MOTILITY (2009)
Glucagon-like peptide-2 increases mesenteric blood flow in humans
Lasse Bremholm et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2009)
Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract
Ida B. Gottschalck et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2008)
Oxyntomodulin differentially affects glucagon-like peptide-1 receptor β-arrestin recruitment and signaling through Gαs
Rasmus Jorgensen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Glucagon-like peptide-2: Update of the recent clinical trials
PB Jeppesen
GASTROENTEROLOGY (2006)
Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans
JJ Meier et al.
GASTROENTEROLOGY (2006)
Role of gastrointestinal hormones in postprandial reduction of bone resorption
DB Henriksen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist
J Thulesen et al.
REGULATORY PEPTIDES (2002)
Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon
PB Jeppesen et al.
GASTROENTEROLOGY (2001)
Share Paper
